Search results
Results From The WOW.Com Content Network
Ethylenediaminetetraacetic acid (EDTA), also called EDTA acid, is an aminopolycarboxylic acid with the formula [CH 2 N(CH 2 CO 2 H) 2] 2. This white, slightly water-soluble solid is widely used to bind to iron (Fe 2+ /Fe 3+) and calcium ions (Ca 2+), forming water-soluble complexes even at neutral pH. It is thus used to dissolve Fe- and Ca ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Chelation therapy is a medical procedure that involves the administration of chelating agents to remove heavy metals from the body. [1] Chelation therapy has a long history of use in clinical toxicology [2] and remains in use for some very specific medical treatments, although it is administered under very careful medical supervision due to various inherent risks, including the mobilization of ...
DOTA is derived from the macrocycle known as cyclen.The four secondary amine groups are modified by replacement of the N-H centers with N-CH 2 CO 2 H groups. The resulting aminopolycarboxylic acid, upon ionization of the carboxylic acid groups, is a high affinity chelating agent for di- and trivalent cations.
Sodium calcium edetate is in the chelating agent family of medication. [3] It is a salt of edetate with two sodium atoms and one calcium atom. [4] It works by binding to a number of heavy metals, which renders them almost inert and allows them to leave the body in the urine.
Although the concept and practical use of metal chelation is common, chelation of inert metals, such as platinum, has been rarely reported and the yield was extremely low. [2] To produce chelated platinum solution, tetraammonium EDTA , NTA, DTPA or HEDTA type chelating agent was mixed with platinum or platinum chemical compounds.
Edotreotide (USAN, also known as (DOTA 0-Phe 1-Tyr 3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. [3] When used therapeutically it is an example of peptide receptor radionuclide therapy.
NCCIH has been criticized by Steven E. Nissen, Stephen Barrett, and Kimball Atwood among others, for funding, along with the National Heart, Lung, and Blood Institute [34] a study of EDTA chelation therapy for coronary artery disease, which lasted about 10 years and cost about $31 million, even though smaller, controlled trials found chelation ...